Perspective Therapeutics (NYSE:CATX) Earns Buy Rating from HC Wainwright

Perspective Therapeutics (NYSE:CATX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 354.55% from the stock’s current price.

CATX has been the topic of a number of other reports. Royal Bank of Canada lowered their price objective on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Thursday. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Scotiabank began coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price target for the company. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, Wedbush reissued an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $14.44.

Perspective Therapeutics Trading Down 4.3 %

Shares of CATX stock opened at $2.20 on Monday. The business’s 50 day moving average is $2.94 and its two-hundred day moving average is $6.29. Perspective Therapeutics has a twelve month low of $2.18 and a twelve month high of $19.05.

Institutional Trading of Perspective Therapeutics

Several large investors have recently bought and sold shares of CATX. Charles Schwab Investment Management Inc. boosted its position in shares of Perspective Therapeutics by 221.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after buying an additional 298,778 shares in the last quarter. State Street Corp raised its position in Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after acquiring an additional 1,192,812 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Perspective Therapeutics by 8.0% in the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after purchasing an additional 355,685 shares in the last quarter. FMR LLC grew its position in shares of Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after purchasing an additional 5,370,392 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of Perspective Therapeutics by 1,302.7% in the third quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock valued at $635,000 after purchasing an additional 44,174 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.